EuroCetus B.V., an Amsterdam-based oncology business unit ofChiron Corp. (NASDAQ:CHIR), said Monday that it receivedapproval to market Proleukin interleukin-2 in theCommonwealth of Independent States (formerly the SovietUnion). EuroCetus will distribute Proleukin in the CIS throughan undisclosed third party.
EuroCetus received its first approval to market Proleukin in1990 as a treatment for metastatic renal cell carcinoma, and isselling Proleukin in 10 European countries. An FDA advisorycommittee recommended U.S. marketing approval in January.
(c) 1997 American Health Consultants. All rights reserved.